Open AccessPB2102: PHASE 2 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
Author(s) -
Michot J.M.,
Koh Y.,
Lee P.,
Jin J.,
Clynes R.,
Kye S.,
Chiarella M.,
Patel K.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851240.74602.7c
Subject(s) - medicine , lenalidomide , cytokine release syndrome , regimen , diffuse large b cell lymphoma , oncology , rituximab , phases of clinical research , cd20 , tumor lysis syndrome , lymphoma , follicular lymphoma , immunology , immunotherapy , clinical trial , cancer , chemotherapy , chimeric antigen receptor , multiple myeloma